Facial Palsy Therapy: Can Novel ‘Smart Spectacles’ Help People Smile?

Ala Szczepura, Amir Khan, Nikki Holliday, Charles Nduka, Catriona Neville, Karen Johnson, Hema Mistry, Sam Oxford

Research output: Contribution to journalMeeting Abstract

Abstract

Introduction: In the United Kingdom (UK), 23,000 people annually are diagnosed with facial palsy (acute onset facial paralysis). For nearly one third this will result in a permanent disability, including in some the inability to smile. In addition to initial pharmacological therapy, guidelines recommend tailored facial exercise (TFE) therapy repeated every day. However, not all patients are currently able to access such specialist physical therapy. ‘Smart specs’ (using miniaturized sensors in the frames to measure facial movement) are currently being developed. Linked to a smartphone, these could allow people to practice TFEs discreetly, provide immediate feedback, and supply data on outcomes to the patient and their clinician.Methods: Modelling of introduction of Facial Remote Activity Monitoring Eyewear (FRAME) into treatment pathways for patients with facial palsy. This included: (i) review on effectiveness of TFE therapy; (ii) national surveys (medical staff, facial therapy specialists and patients) to gather data on access to TFE therapy; (iii) Delphi Exercise to identify consensus on key outcome measures; and, (iv) economic modelling to estimate cost-effectiveness and determine a range of acceptable costs for the technology. In parallel, research to examine target markets to inform product development, and production of integral commercialization plan. Results: Searches short-listed ten studies to add to the three included in the 2011 Cochrane review. Surveys indicate approximately thirteen percent of eligible UK patients access personalized TFE therapy. Estimated annual expenditure on hospital treatments for facial palsy patients is currently GBP >80 million (>USD 106 million) compared with <£0.5 million (<USD 0.66 million) on TFE therapy. Patients with permanent defects can suffer a loss of up to two quality-adjusted life years (QALYs).Conclusions: Findings from this study, particularly in relation to costs and benefits, will inform the design of a subsequent randomized controlled trial. A novel wearable technology could make a major difference to people’s lives, as well as generating potential efficiencies for healthcare.
LanguageEnglish
Pages76
Number of pages1
JournalInternational Journal of Technology Assessment in Health Care
Volume34
Issue numberS1
DOIs
Publication statusPublished - 3 Jan 2019

Fingerprint

Facial Paralysis
Exercise Therapy
Therapeutics
Cost-Benefit Analysis
Technology
Quality-Adjusted Life Years
Medical Staff
Polytetrafluoroethylene
Health Expenditures
Randomized Controlled Trials
Economics
Outcome Assessment (Health Care)
Pharmacology
Guidelines
Exercise
Delivery of Health Care
Costs and Cost Analysis
Research

Cite this

Facial Palsy Therapy : Can Novel ‘Smart Spectacles’ Help People Smile? / Szczepura, Ala; Khan, Amir; Holliday, Nikki; Nduka, Charles; Neville, Catriona; Johnson, Karen; Mistry, Hema; Oxford, Sam.

In: International Journal of Technology Assessment in Health Care, Vol. 34, No. S1, 03.01.2019, p. 76.

Research output: Contribution to journalMeeting Abstract

@article{e014eba5e1a94c54909670581cce7a63,
title = "Facial Palsy Therapy: Can Novel ‘Smart Spectacles’ Help People Smile?",
abstract = "Introduction: In the United Kingdom (UK), 23,000 people annually are diagnosed with facial palsy (acute onset facial paralysis). For nearly one third this will result in a permanent disability, including in some the inability to smile. In addition to initial pharmacological therapy, guidelines recommend tailored facial exercise (TFE) therapy repeated every day. However, not all patients are currently able to access such specialist physical therapy. ‘Smart specs’ (using miniaturized sensors in the frames to measure facial movement) are currently being developed. Linked to a smartphone, these could allow people to practice TFEs discreetly, provide immediate feedback, and supply data on outcomes to the patient and their clinician.Methods: Modelling of introduction of Facial Remote Activity Monitoring Eyewear (FRAME) into treatment pathways for patients with facial palsy. This included: (i) review on effectiveness of TFE therapy; (ii) national surveys (medical staff, facial therapy specialists and patients) to gather data on access to TFE therapy; (iii) Delphi Exercise to identify consensus on key outcome measures; and, (iv) economic modelling to estimate cost-effectiveness and determine a range of acceptable costs for the technology. In parallel, research to examine target markets to inform product development, and production of integral commercialization plan. Results: Searches short-listed ten studies to add to the three included in the 2011 Cochrane review. Surveys indicate approximately thirteen percent of eligible UK patients access personalized TFE therapy. Estimated annual expenditure on hospital treatments for facial palsy patients is currently GBP >80 million (>USD 106 million) compared with <£0.5 million (<USD 0.66 million) on TFE therapy. Patients with permanent defects can suffer a loss of up to two quality-adjusted life years (QALYs).Conclusions: Findings from this study, particularly in relation to costs and benefits, will inform the design of a subsequent randomized controlled trial. A novel wearable technology could make a major difference to people’s lives, as well as generating potential efficiencies for healthcare.",
author = "Ala Szczepura and Amir Khan and Nikki Holliday and Charles Nduka and Catriona Neville and Karen Johnson and Hema Mistry and Sam Oxford",
year = "2019",
month = "1",
day = "3",
doi = "10.1017/S0266462318001964",
language = "English",
volume = "34",
pages = "76",
journal = "International Journal of Technology Assessment in Health Care",
issn = "0266-4623",
publisher = "Cambridge University Press",
number = "S1",

}

TY - JOUR

T1 - Facial Palsy Therapy

T2 - International Journal of Technology Assessment in Health Care

AU - Szczepura, Ala

AU - Khan, Amir

AU - Holliday, Nikki

AU - Nduka, Charles

AU - Neville, Catriona

AU - Johnson, Karen

AU - Mistry, Hema

AU - Oxford, Sam

PY - 2019/1/3

Y1 - 2019/1/3

N2 - Introduction: In the United Kingdom (UK), 23,000 people annually are diagnosed with facial palsy (acute onset facial paralysis). For nearly one third this will result in a permanent disability, including in some the inability to smile. In addition to initial pharmacological therapy, guidelines recommend tailored facial exercise (TFE) therapy repeated every day. However, not all patients are currently able to access such specialist physical therapy. ‘Smart specs’ (using miniaturized sensors in the frames to measure facial movement) are currently being developed. Linked to a smartphone, these could allow people to practice TFEs discreetly, provide immediate feedback, and supply data on outcomes to the patient and their clinician.Methods: Modelling of introduction of Facial Remote Activity Monitoring Eyewear (FRAME) into treatment pathways for patients with facial palsy. This included: (i) review on effectiveness of TFE therapy; (ii) national surveys (medical staff, facial therapy specialists and patients) to gather data on access to TFE therapy; (iii) Delphi Exercise to identify consensus on key outcome measures; and, (iv) economic modelling to estimate cost-effectiveness and determine a range of acceptable costs for the technology. In parallel, research to examine target markets to inform product development, and production of integral commercialization plan. Results: Searches short-listed ten studies to add to the three included in the 2011 Cochrane review. Surveys indicate approximately thirteen percent of eligible UK patients access personalized TFE therapy. Estimated annual expenditure on hospital treatments for facial palsy patients is currently GBP >80 million (>USD 106 million) compared with <£0.5 million (<USD 0.66 million) on TFE therapy. Patients with permanent defects can suffer a loss of up to two quality-adjusted life years (QALYs).Conclusions: Findings from this study, particularly in relation to costs and benefits, will inform the design of a subsequent randomized controlled trial. A novel wearable technology could make a major difference to people’s lives, as well as generating potential efficiencies for healthcare.

AB - Introduction: In the United Kingdom (UK), 23,000 people annually are diagnosed with facial palsy (acute onset facial paralysis). For nearly one third this will result in a permanent disability, including in some the inability to smile. In addition to initial pharmacological therapy, guidelines recommend tailored facial exercise (TFE) therapy repeated every day. However, not all patients are currently able to access such specialist physical therapy. ‘Smart specs’ (using miniaturized sensors in the frames to measure facial movement) are currently being developed. Linked to a smartphone, these could allow people to practice TFEs discreetly, provide immediate feedback, and supply data on outcomes to the patient and their clinician.Methods: Modelling of introduction of Facial Remote Activity Monitoring Eyewear (FRAME) into treatment pathways for patients with facial palsy. This included: (i) review on effectiveness of TFE therapy; (ii) national surveys (medical staff, facial therapy specialists and patients) to gather data on access to TFE therapy; (iii) Delphi Exercise to identify consensus on key outcome measures; and, (iv) economic modelling to estimate cost-effectiveness and determine a range of acceptable costs for the technology. In parallel, research to examine target markets to inform product development, and production of integral commercialization plan. Results: Searches short-listed ten studies to add to the three included in the 2011 Cochrane review. Surveys indicate approximately thirteen percent of eligible UK patients access personalized TFE therapy. Estimated annual expenditure on hospital treatments for facial palsy patients is currently GBP >80 million (>USD 106 million) compared with <£0.5 million (<USD 0.66 million) on TFE therapy. Patients with permanent defects can suffer a loss of up to two quality-adjusted life years (QALYs).Conclusions: Findings from this study, particularly in relation to costs and benefits, will inform the design of a subsequent randomized controlled trial. A novel wearable technology could make a major difference to people’s lives, as well as generating potential efficiencies for healthcare.

U2 - 10.1017/S0266462318001964

DO - 10.1017/S0266462318001964

M3 - Meeting Abstract

VL - 34

SP - 76

JO - International Journal of Technology Assessment in Health Care

JF - International Journal of Technology Assessment in Health Care

SN - 0266-4623

IS - S1

ER -